Abstracts

TOWARD DURABLE CONTROL OF HIV-1 WITH eCD4-Ig

eCD4-Ig is an exceptionally broad HIV-1 entry inhibitor that uniquely neutralizes all of the 270 HIV-1, HIV-2 and SIV isolates it has been tested against, in every case with IC80 values < 10 µg/ml.  eCD4-Ig’s breadth and potency derives from the fact that it closely and simultaneously mimics the HIV-1 receptor CD4 and the HIV-1…

CHLAMYDIA AND GONORRHOEA IN PREGNANCY: SILENCE OF THE GERMS

Sex causes pregnancy, HIV infection and bacterial sexually transmitted infections (STI). Every year, women aged 15-49 years will experience about 63.8 million new infections caused by Chlamydia trachomatis (chlamydia) and 37.1 million caused by Neisseria gonorrhoeae (gonorrhoea). These estimated incidence rates are highest in southern sub-Saharan Africa and Oceania regions and in women under 25…

BEYOND THE STIGMA: A SORELY NEEDED PERSPECTIVE ON HSV

HSV-1 and 2 infections are common across the globe with recent prevalence estimates of 3709 million cases of HSV-1 (including 140 million cases of genital HSV-1 infection) and 417 million cases of HSV-2 infection.  Women are at higher risk and acquire HSV-2 at a younger age than men.   Prevalent HSV-2 increases risk of HIV acquisition…

REFLECTIONS ON THE UK EPIDEMIC

For the third year running, reports of new HIV diagnoses among men and women fell dramatically in the England largely driven by a decline in new diagnoses among gay, bisexual and other men who have sex with men (GBM) residing in London. A CD4 back-calculation model indicates that transmission among GBM has fallen since 2012…

SYPHILIS CAUSES STILLBIRTH: PENICILLIN IS PREVENTION

WHO estimates 660,000 cases of mother-to-child transmission of syphilis (congenital syphilis) occurred in 2016, resulting in 350,000 adverse birth outcomes inclusive of over 200,000 stillbirths and neonatal deaths.  By comparison, UNAIDS estimates approximately 180,000 new cases of HIV occurred in 2016 among children ages 0-14 years. Although over 90% of countries include screening of pregnant…

DECREASING COMMUNITY VIREMIA IS ASSOCIATED WITH DECREASING HIV INCIDENCE IN AUSTRALIA

Considerable public health resources have been dedicated to implementing HIV ‘treatment-as-prevention’ in an effort to reduce new infections. Although promising, no large-scale studies have yet evaluated the community-level impact of treatment-as-prevention on direct measures of HIV incidence among gay and bisexual men (GBM). This study assessed the temporal relationship between community viremia and HIV incidence…

LRA 2.0: IMMUNE-BASED LATENCY REVERSAL

Long-lasting, latently-infected resting CD4+ T cells are the greatest obstacle to curing HIV infection, as these cells can persist despite decades of treatment with antiretroviral therapy. One approach towards a cure is to reactivate HIV from its latent state, thus promoting virus mediated killing and/or facilitating immune recognition and clearance of infected cells. Interventions that…

IN VIVO MODELS FOR THE EVALUATION OF NOVEL HIV CURE INTERVENTIONS

Animal models have contributed extensively to biomedical investigation and specifically to virtually all areas of HIV research.  Animal models provide a complex substrate for the evaluation of novel therapeutic interventions at very early stages that would not be suitable for testing in humans.  They allow for exquisite control of variables that are normally impossible to control in…